Stock MYGN MYRIAD GENETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
24.9 USD -0.20% Intraday chart for Myriad Genetics, Inc. +1.80% +30.09%
Jun. 27 Scotiabank Initiates Myriad Genetics at Sector Outperform MT
Jun. 12 Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Myriad Genetics Earns 2024 Great Place To Work® Certification™
GL
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
GL
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
GL
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
GL
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
AQ
NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE LITIGATION TO: ALL CURRENT STOCKHOLDERS OF MYRIAD GENETICS, INC. (NASDAQ SYMBOL: MYGN) - Form 8-K
PU
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
GL
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
GL
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
GL
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
GL
Myriad: Q1 Earnings Snapshot
AQ
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
GL
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
GL
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
GL
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen
AQ
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
GL
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
AQ
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. News Myriad Genetics, Inc.
  5. Press Releases